APA (7th ed.) Citation

Younes, A., Connors, J. M., Park, S. I., Fanale, M., O'Meara, M. M., Hunder, N. N., . . . Ansell, S. M. (2013). Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study. The lancet oncology, 14(13), 1348-1356. https://doi.org/10.1016/S1470-2045(13)70501-1

Chicago Style (17th ed.) Citation

Younes, Anas, Joseph M. Connors, Steven I. Park, Michelle Fanale, Megan M. O'Meara, Naomi N. Hunder, Dirk Huebner, and Stephen M. Ansell. "Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Hodgkin's Lymphoma: A Phase 1, Open-label, Dose-escalation Study." The Lancet Oncology 14, no. 13 (2013): 1348-1356. https://doi.org/10.1016/S1470-2045(13)70501-1.

MLA (9th ed.) Citation

Younes, Anas, et al. "Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Hodgkin's Lymphoma: A Phase 1, Open-label, Dose-escalation Study." The Lancet Oncology, vol. 14, no. 13, 2013, pp. 1348-1356, https://doi.org/10.1016/S1470-2045(13)70501-1.